Literature DB >> 2990824

A presumptive role for leukotrienes in obstructive airways diseases.

R A Lewis.   

Abstract

The likelihood that the leukotriene products derived from the 5-lipoxygenase pathway mediate aspects of obstructive airways diseases is strongly suggested by their documented capacities to effect airway spasmogenicity, airway hyperreactivity, tissue edema formation, mucus secretion, and tissue infiltration by leukocytes. That the various leukotriene components of SRS-A have unique receptors on responding tissues and are recoverable from airway surfaces in several inflammatory lung diseases and that several resident and infiltrating cell types have significant potential for leukotriene biosynthesis lend further support to their postulated pathobiologic roles. To fulfill Koch's postulates for proof of leukotrienes' etiologic role, it remains to be shown that inhibition of their biosynthesis or specific antagonism at their end-organ receptors can greatly ameliorate these disease states.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990824     DOI: 10.1378/chest.88.2_supplement.98s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Pharmacological modulation of bronchial anaphylaxis induced by aerosol challenge in anaesthetized guinea-pigs.

Authors:  L Daffonchio; I W Lees; A N Payne; B J Whittle
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

2.  Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.

Authors:  J E Tateson; R W Randall; C H Reynolds; W P Jackson; P Bhattacherjee; J A Salmon; L G Garland
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

3.  Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs.

Authors:  A N Payne; L G Garland; I W Lees; J A Salmon
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.